
### [MONDO:0018795](http://purl.obolibrary.org/obo/MONDO_0018795)
**Label:** syndromic constitutional thrombocytopenia

**Subclasses:** [MONDO:0010518](http://purl.obolibrary.org/obo/MONDO_0010518) (Wiskott-Aldrich syndrome), [MONDO:0016502](http://purl.obolibrary.org/obo/MONDO_0016502) (Hermansky-Pudlak syndrome without pulmonary fibrosis), [MONDO:0016501](http://purl.obolibrary.org/obo/MONDO_0016501) (Hermansky-Pudlak syndrome with pulmonary fibrosis), [MONDO:0019312](http://purl.obolibrary.org/obo/MONDO_0019312) (Hermansky-Pudlak syndrome), [MONDO:0011555](http://purl.obolibrary.org/obo/MONDO_0011555) (radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome), [MONDO:0011071](http://purl.obolibrary.org/obo/MONDO_0011071) (hereditary thrombocytopenia with normal platelets-hematological cancer predisposition syndrome), [MONDO:0011603](http://purl.obolibrary.org/obo/MONDO_0011603) (GNE myopathy), [MONDO:0015912](http://purl.obolibrary.org/obo/MONDO_0015912) (MYH-9 related disease), [MONDO:0020118](http://purl.obolibrary.org/obo/MONDO_0020118) (dense granule disease), 

**Corr. equiv. classes:** [OMIM:301000](http://purl.obolibrary.org/obo/OMIM_301000), [OMIM:605432](http://purl.obolibrary.org/obo/OMIM_605432), [OMIM:601399](http://purl.obolibrary.org/obo/OMIM_601399), [OMIM:605820](http://purl.obolibrary.org/obo/OMIM_605820), [Orphanet:71290](http://www.orpha.net/ORDO/Orphanet_71290), [Orphanet:231512](http://www.orpha.net/ORDO/Orphanet_231512), [Orphanet:231500](http://www.orpha.net/ORDO/Orphanet_231500), [Orphanet:182050](http://www.orpha.net/ORDO/Orphanet_182050), [Orphanet:906](http://www.orpha.net/ORDO/Orphanet_906), [Orphanet:71289](http://www.orpha.net/ORDO/Orphanet_71289), [Orphanet:602](http://www.orpha.net/ORDO/Orphanet_602), [Orphanet:79430](http://www.orpha.net/ORDO/Orphanet_79430), [OMIM:277970](http://purl.obolibrary.org/obo/OMIM_277970), [Orphanet:98456](http://www.orpha.net/ORDO/Orphanet_98456), 

**Class expressions from DL-Learner:**

- [HP:0000421](http://purl.obolibrary.org/obo/HP_0000421) (Epistaxis) and [HP:0001872](http://purl.obolibrary.org/obo/HP_0001872) (Abnormality of thrombocytes) and [HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system) 55.11%
- [HP:0000421](http://purl.obolibrary.org/obo/HP_0000421) (Epistaxis) and [HP:0001872](http://purl.obolibrary.org/obo/HP_0001872) (Abnormality of thrombocytes) and [HP:0001881](http://purl.obolibrary.org/obo/HP_0001881) (Abnormality of leukocytes) 55.11%
- [HP:0000421](http://purl.obolibrary.org/obo/HP_0000421) (Epistaxis) and [HP:0001872](http://purl.obolibrary.org/obo/HP_0001872) (Abnormality of thrombocytes) and [HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system) and [HP:0011354](http://purl.obolibrary.org/obo/HP_0011354) (Generalized abnormality of skin) 55.11%
- [HP:0000421](http://purl.obolibrary.org/obo/HP_0000421) (Epistaxis) and [HP:0001872](http://purl.obolibrary.org/obo/HP_0001872) (Abnormality of thrombocytes) and [HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system) and [HP:0011276](http://purl.obolibrary.org/obo/HP_0011276) (Vascular skin abnormality) 55.11%
- [HP:0000421](http://purl.obolibrary.org/obo/HP_0000421) (Epistaxis) and [HP:0001872](http://purl.obolibrary.org/obo/HP_0001872) (Abnormality of thrombocytes) and [HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system) and [HP:0011121](http://purl.obolibrary.org/obo/HP_0011121) (Abnormality of skin morphology) 55.11%
- [HP:0000421](http://purl.obolibrary.org/obo/HP_0000421) (Epistaxis) and [HP:0001872](http://purl.obolibrary.org/obo/HP_0001872) (Abnormality of thrombocytes) and [HP:0002597](http://purl.obolibrary.org/obo/HP_0002597) (Abnormality of the vasculature) and [HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system) 55.11%
- [HP:0000421](http://purl.obolibrary.org/obo/HP_0000421) (Epistaxis) and [HP:0001872](http://purl.obolibrary.org/obo/HP_0001872) (Abnormality of thrombocytes) and [HP:0001933](http://purl.obolibrary.org/obo/HP_0001933) (Subcutaneous hemorrhage) and [HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system) 55.11%
- [HP:0000421](http://purl.obolibrary.org/obo/HP_0000421) (Epistaxis) and [HP:0001872](http://purl.obolibrary.org/obo/HP_0001872) (Abnormality of thrombocytes) and [HP:0001881](http://purl.obolibrary.org/obo/HP_0001881) (Abnormality of leukocytes) and [HP:0011354](http://purl.obolibrary.org/obo/HP_0011354) (Generalized abnormality of skin) 55.11%
- [HP:0000421](http://purl.obolibrary.org/obo/HP_0000421) (Epistaxis) and [HP:0001872](http://purl.obolibrary.org/obo/HP_0001872) (Abnormality of thrombocytes) and [HP:0001881](http://purl.obolibrary.org/obo/HP_0001881) (Abnormality of leukocytes) and [HP:0011276](http://purl.obolibrary.org/obo/HP_0011276) (Vascular skin abnormality) 55.11%
- [HP:0000421](http://purl.obolibrary.org/obo/HP_0000421) (Epistaxis) and [HP:0001872](http://purl.obolibrary.org/obo/HP_0001872) (Abnormality of thrombocytes) and [HP:0001881](http://purl.obolibrary.org/obo/HP_0001881) (Abnormality of leukocytes) and [HP:0011121](http://purl.obolibrary.org/obo/HP_0011121) (Abnormality of skin morphology) 55.11%
- [HP:0000421](http://purl.obolibrary.org/obo/HP_0000421) (Epistaxis) and [HP:0001872](http://purl.obolibrary.org/obo/HP_0001872) (Abnormality of thrombocytes) and [HP:0001881](http://purl.obolibrary.org/obo/HP_0001881) (Abnormality of leukocytes) and [HP:0002597](http://purl.obolibrary.org/obo/HP_0002597) (Abnormality of the vasculature) 55.11%
- [HP:0000421](http://purl.obolibrary.org/obo/HP_0000421) (Epistaxis) and [HP:0001872](http://purl.obolibrary.org/obo/HP_0001872) (Abnormality of thrombocytes) and [HP:0001881](http://purl.obolibrary.org/obo/HP_0001881) (Abnormality of leukocytes) and [HP:0001933](http://purl.obolibrary.org/obo/HP_0001933) (Subcutaneous hemorrhage) 55.11%
- [HP:0000421](http://purl.obolibrary.org/obo/HP_0000421) (Epistaxis) and [HP:0001626](http://purl.obolibrary.org/obo/HP_0001626) (Abnormality of the cardiovascular system) and [HP:0001872](http://purl.obolibrary.org/obo/HP_0001872) (Abnormality of thrombocytes) and [HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system) 55.11%
- [HP:0000421](http://purl.obolibrary.org/obo/HP_0000421) (Epistaxis) and [HP:0001626](http://purl.obolibrary.org/obo/HP_0001626) (Abnormality of the cardiovascular system) and [HP:0001872](http://purl.obolibrary.org/obo/HP_0001872) (Abnormality of thrombocytes) and [HP:0001881](http://purl.obolibrary.org/obo/HP_0001881) (Abnormality of leukocytes) 55.11%
- [HP:0000421](http://purl.obolibrary.org/obo/HP_0000421) (Epistaxis) and [HP:0001574](http://purl.obolibrary.org/obo/HP_0001574) (Abnormality of the integument) and [HP:0001872](http://purl.obolibrary.org/obo/HP_0001872) (Abnormality of thrombocytes) and [HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system) 55.11%


